Matrisome Bio

Matrisome Bio is developing innovative therapies that deliver potent payloads directly to the extracellular matrix (ECM) of tumors and metastases, maximizing precision and sparing healthy tissue. Our proprietary ECM-specific, nanobody-based binders transform the tumor environment into a high-retention drug depot. Our lead asset is an ECM-targeted radiopharmaceutical, and our platform supports a broad pipeline including antibody-drug conjugates, immunomodulatory therapies, and fibrosis-targeted treatments.